ST. LOUIS, Oct. 13, 2021 /PRNewswire/ – Geneoscopy
Inc., a life sciences company focused on the development of
diagnostic tests for gastrointestinal health, today announced that
Goldman Sachs (NYSE: GS) is recognizing the company's co-founder
and CEO, Andrew Barnell, as one of
the 100 Most Intriguing Entrepreneurs of 2021 at its Builders +
Innovators Summit in Healdsburg,
California.
Goldman Sachs selected Barnell as one of 100 entrepreneurs from
multiple industries to be honored at the two-day event. Barnell
began his career with J.P. Morgan's healthcare investment banking
group, working primarily on M&A and capital markets
transactions. Prior to co-founding Geneoscopy, he was an associate
at Lindsay Goldberg, a middle-market private equity firm focused on
partnering with family-owned businesses. Barnell holds a BA in
Applied Economics and Management, with a specialization in Finance,
from Cornell University and earned an
MBA in Health Care Management and Entrepreneurial Management from
The Wharton School.
"We are honored to have Andrew recognized as part of this
distinguished group of entrepreneurs," commented Vince Wong, Geneoscopy's Chief Commercial
Officer. "With an initial focus on colorectal cancer prevention,
Geneoscopy's technology is poised to transform gastrointestinal
health by enabling earlier detection, more accurate diagnosis, and
more effective therapeutic management. It is exciting to have
Andrew's vision for the company recognized, validating the
significant impact it will have on shaping the future of
gastrointestinal health."
"Innovation doesn't happen just anywhere; it thrives where
there's a wide range of thoughts and perspectives," said
David M. Solomon, Chairman & CEO
of Goldman Sachs. "One of our great strengths is our ability to
bring together people from different walks of life and to spark
conversations today that will lead to breakthroughs tomorrow. The
leaders we've chosen to highlight at our Builders + Innovators
Summit are truly remarkable, and we are pleased to recognize Andrew
as one of this year's most intriguing entrepreneurs."
In addition to honoring 100 entrepreneurs, the summit consists
of general sessions and clinics led by seasoned entrepreneurs,
academics, and business leaders as well as resident scholars.
About Geneoscopy Inc.
Geneoscopy Inc. is a life sciences company focused on the
development of diagnostic tests for gastrointestinal health.
Geneoscopy's lead diagnostic uses stool-derived eukaryotic RNA
(seRNA) to detect colorectal cancer and precancerous adenomas. This
device was awarded Breakthrough Device Designation from the US FDA
for its ability to reduce morbidity associated with colorectal
cancer through advanced adenoma detection. Indicative of its
breakthrough status, preliminary trials suggest that the diagnostic
can detect these lesions at a higher rate than all existing
noninvasive screening tests. Visit geneoscopy.com to
learn more.
Geneoscopy Inc. Forward-Looking Statements
The information contained in this release includes information
about Geneoscopy's future plans concerning its noninvasive
molecular test that can detect colorectal cancer and precancerous
adenomas, and as such constitute forward-looking statements. These
forward-looking statements are based upon the Company's reasonable
estimates of future results or trends. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of the Company's
control. Geneoscopy's actual results and financial condition may
differ materially from those indicated in the forward-looking
statements. Although the Company believes that its business plans
and objectives reflected in or suggested by these forward-looking
statements are reasonable, such plans or objectives may not be
achieved and the actual results may differ substantially from the
projected results.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/geneoscopy-honored-by-goldman-sachs-for-entrepreneurship-301398980.html
SOURCE Geneoscopy Inc.